Synthego was founded in 2012 by Alex Pesch, Michael Dabrowski, and Paul Dabrowski. When asked about a potential IPO, CEO Dabrowski said that while "We think we can basically be ready for that anytime... From a publicity standpoint, from a people and teams standpoint, a financial capital needs standpoint, now we’ve decided to stay private." These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.
Synthego is a genome engineering company leveraging machine learning, automation, and gene editing to build platforms at scale. The company is a major developer of the tools which are used in CRISPR therapies, citing more than 1,000 peer-reviewed studies that have used its technology in at least one step. The company has raised more than $450 million in venture capital funding from investors including Perceptive Advisors LLC, SoftBank Vision Fund 2, Moore Strategic Ventures, Declaration Partners, Laurion Capital Management, and Logos Capital. Synthego did not release valuation information after a $200 million equity round in early 2022, but it is estimated at between $800 million and $1.2 billion.
Synthego is a private company and not publicly traded.
If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.
Synthego has not yet filed for an IPO. However, it's important to note that IPOs are not the sole avenue for a private company to transition to public trading. Private companies can also go public through alternative methods such as but limited to Special Purpose Acquisition Companies (SPACs), direct listings, or through mergers and acquisitions. Find out which companies are eyeing an IPO on our Tech IPO Calendar 2024.
Synthego is privately held company and is not publicly traded, therefor investing in Synthego pre-IPO is only available to accredited investors. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to invest in private companies before their potential IPO. If you are not an accredited investor, discover how to begin the the process to potentially qualify for new investment opportunities.
To determine the value of your Synthego shares, create a free account to gain access to Forge’s platform. Forge Markets contains pricing information for hundreds of pre-IPO companies. A Private Market Specialist will also be available to assist you with any inquiries related to your Synthego shares. You can also learn more about how to sell your private shares before getting started.
Yes, you can seek to sell shares in Synthego while it remains private. If you are considering selling, you can register today for free to get started. Once registered, a Private Market Specialist will guide you through any questions you might have. You may also continue to browse through our resources to help you understand the implications and procedures involved in selling your private market shares.
Date | Funding Round | Funding Raised | Price per Share | Last Known Valuation |
---|---|---|---|---|
2/17/2022 | Series E |
$144.17MM raised | $XXX.XX | $XXX.XX |
8/26/2020 | Series D |
$100MM raised | $XXX.XX | $XXX.XX |
10/23/2018 | Series C |
$116.27MM raised | $XXX.XX | $XXX.XX |
1/4/2017 | Series B and B-1 |
$46.33MM raised | $XXX.XX | $XXX.XX |
7/5/2013 | Series A |
$8.3MM raised | $XXX.XX | $XXX.XX |